Odyssey Therapeutics, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and inflammatory diseases. The company’s current pipeline is centered on precision therapies designed to target disease-driving pathways, with programs spanning small molecules and protein therapeutics. Its research includes candidates aimed at key immune system mechanisms such as RIPK2, SLC15A4, IRAK4, and TNFR2, reflecting a broader strategy to address complex immune-mediated conditions. Odyssey Therapeutics serves the healthcare and biotechnology markets, where it contributes to the development of targeted treatments for patients with significant unmet medical needs. Headquartered in Boston, Massachusetts, Odyssey Therapeutics combines discovery and development capabilities across immunology and related therapeutic areas, positioning itself as a specialized player in modern drug development.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Gary D. Glick Ph.D.
- Employees
- 100
- Headquarters
- Boston, MA, United States
- Website
- odysseytx.com